Evolus (EOLS) announced that its Chief Financial Officer, Sandra Beaver, has resigned effective June 13, 2025, to accept the same position at a private mental health and wellness technology company. Ms. Beaver’s resignation is not a result of any disagreement related to the company’s operations, policies or practices, including any accounting principles and practices, or related to any financial statements or disclosures.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EOLS:
- Evolus announces publication of U.S. pivotal study for Evolysse injectable gels
- Evolus, Inc. Reports Strong Q1 Growth Amid Challenges
- Evolus’s Strong Market Position and Growth Prospects Justify Buy Rating Despite Revenue Miss
- Evolus’s Growth Potential and Market Resilience: Analyst Recommends Buy Rating
- Evolus: Strong Growth Potential and Market Expansion Drive Buy Rating